Skip to main content
Clinical Trials/NCT03599492
NCT03599492
Completed
Not Applicable

The Effect of Transjugular Intraheptic Portosystemic Shunt (TIPS) on Gastrointestinal Motility and the Gut Microbiota

NYU Langone Health1 site in 1 country14 target enrollmentNovember 2016
ConditionsCirrhosis

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Cirrhosis
Sponsor
NYU Langone Health
Enrollment
14
Locations
1
Primary Endpoint
Post TIPS intestinal transit time (measured in hours and minutes), via smart pill in patients with cirrhosis
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

The effect of portal hypertension on gastrointestinal motility, and how reversal or improvement in portal hypertension may alter gastrointestinal motility, remains unclear and further research is needed. Additionally, patients with cirrhosis have altered gut microflora, particularly rich in lactobacilli, including enterococci and bifidobacteria. Transjugular Intraheptic Portosystemic Shunting (TIPS) is a procedure performed by interventional radiologists, in which a connection is made between the portal and venous circulations, allowing high pressure portal blood to more easily enter the systemic circulation and bypass the liver; thus effectively decreased portal pressure.

Registry
clinicaltrials.gov
Start Date
November 2016
End Date
April 12, 2022
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients with either radiographic or biopsy proven decompensated cirrhosis (as determined by ascites, variceal hemorrhage, encephalopathy or jaundice).
  • Patients undergoing an elective TIPS for any standard of care established indication (examples: worsening ascites, recurrent variceal bleeding).

Exclusion Criteria

  • Pregnant women.
  • Patients unwilling or unable to provide informed consent.
  • Patients undergoing an emergent TIPS for acute or subacute variceal hemorrhage.
  • Patients with diabetes, significant cardiovascular, renal or other chronic disease which has been known to affect intestinal motility.
  • Previously diagnosed gastroparesis or other GI dysmotility disorder.
  • Patients currently taking narcotics, antibiotics excluding rifaximin, prokinetic medications or lactulose.
  • Patients with a history of gastric bezoar.
  • Patients with a history of multiple intestinal surgeries or GI surgery within the past 3 months.
  • Patients with a history of gastrointestinal strictures, fistulas, or physiological or mechanical obstruction.
  • Patients with a history of gastrointestinal strictures, fistulas, or physiological or mechanical obstruction.

Outcomes

Primary Outcomes

Post TIPS intestinal transit time (measured in hours and minutes), via smart pill in patients with cirrhosis

Time Frame: 14 Weeks

Due to small sample size, Wilcoxon rank-sum test will be used to compare the continuous variable of gut transit times. A p-value of \<0.05 will be considered statistically significant.

Pre-TIPS intestinal transit time (measured in hours and minutes), via smart pill in patients with cirrhosis

Time Frame: 14 Weeks

Due to small sample size, Wilcoxon rank-sum test will be used to compare the continuous variable of gut transit times. A p-value of \<0.05 will be considered statistically significant.

Study Sites (1)

Loading locations...

Similar Trials